Pricing Log in Create free account
Friday 6 November 2026 Export CRL’s income statement to Excel — free account

Charles River Laboratories International, Inc.

CRL Healthcare Diagnostics & Research

Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024.

Revenue
−2.20%
EPS
+530.3%
Free cash flow
+16.3%
Total debt
+11.8%

Quarter to September 2026, against a year earlier

328.72 15.70 +5.02%
Market cap
$14.9B
P/E
300×
Fwd P/E
89.2×
Dividend yield
—
F-score
5/9
Altman Z
2.40
Beneish M
−3.11
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Charles River Laboratories International, Inc. (CRL) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
10-Q Sep 26, 2026 P1I2: 8 added · 7 removed · 32 modified
P2I1A: no comparison — incorporated by reference
8-K Nov 4, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Sep 24, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Jun 27, 2026 P1I2: 25 added · 5 removed · 34 modified
P2I1A: no comparison — incorporated by reference 		Inventory outpacing revenue
8-K Aug 5, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 5, 2026 5.02 Departure or appointment of directors or officers; 5.07 Submission of matters to a vote of security holders; 9.01 Financial statements and exhibits Officer departure
10-Q Mar 28, 2026 P1I2: 16 added · 38 removed · 24 modified
P2I1A: 12 added
8-K May 7, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 25, 2026 7.01 Regulation FD disclosure
8-K Feb 18, 2026 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits
10-K Dec 27, 2025 1: 9 added · 2 removed · 77 modified
1A: 21 added · 1 removed · 58 modified
7: 21 added · 15 removed · 47 modified 		Impairment
8-K Feb 18, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 13, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure
8-K Jan 8, 2026 5.02 Departure or appointment of directors or officers
8-K Dec 3, 2025 7.01 Regulation FD disclosure
8-K Nov 14, 2025 8.01 Other events
10-Q Sep 27, 2025 P1I2: 8 added · 6 removed · 36 modified
P2I1A: 6 added · 8 modified
8-K Nov 5, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K/A Sep 12, 2025 5.02 Departure or appointment of directors or officers
8-K Sep 12, 2025 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Jun 28, 2025 P1I2: 22 added · 3 removed · 28 modified
P2I1A: 1 added · 6 modified
8-K Aug 6, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 29, 2025
8-K May 7, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 28, 2024
8-K Feb 19, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 28, 2024
8-K Nov 6, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 29, 2024
8-K Aug 7, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 9, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 14, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Nov 8, 2023 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.